> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Kyverna Gets Fast Track for Lupus Nephritis Drug
- URL: https://www.fdaweb.com/kyverna-gets-fast-track-for-lupus-nephritis-drug/
- Published: 2023-06-02T12:00:00.000Z
- Updated: 2026-09-14T18:36:03.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5154601

FDA has granted Kyverna Therapeutics a fast track designation for KYV-101, an anti-CD19 chimeric antigen receptor T-cell therapy for treating patients with refractory lupus nephritis. KYV-101 is designed to deplete B cells, including autoreactive B cells, in autoimmune disease patients, the company says, adding that a Phase 1 open-label, multi-center clinical trial of KYV-101 in the U.S. is actively recruiting patients. 

Additionally, in an earlier 20-patient Phase 1/2 study of KYV-101 in oncology, the “expected anti-lymphoma activity was associated with a significant reduction of cytokines released that translated into a strong reduction of cytokine-driven side effects, such as the rate of immune effector cells-associated neurotoxicity syndrome,” the company says. Data also showed that therapy was associated with reduced immunogenicity that “favorably impacted cell persistence,” it says.